BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Academic Article uri icon



  • The combination of clarithromycin, lenalidomide, and dexamethasone (BiRd) was evaluated as therapy for treatment-naive symptomatic multiple myeloma (MM), with overall response at 2 years of 90%. We reviewed the long-term follow-up of initial BiRd therapy. Seventy-two patients were given dexamethasone 40 mg weekly, clarithromycin 500 mg twice daily, and lenalidomide 25 mg daily on days 1 to 21 of a 28-day cycle. After a median follow-up of 6.6 years, overall response rates were 93%, with a very good partial response or better of 68%. Median progression-free survival was 49 months. Evaluation for the development of second primary malignancies (SPMs) was conducted, and no increase in incidence was noted in our cohort of patients who received frontline immunomodulatory therapy. BiRd remains a highly potent and safe regimen for frontline therapy in patients with MM without apparent increase in risk of SPMs. This trial was registered at as #NCT00151203.

publication date

  • January 8, 2013



  • Antineoplastic Combined Chemotherapy Protocols
  • Clarithromycin
  • Clinical Trials, Phase II as Topic
  • Dexamethasone
  • Multiple Myeloma
  • Thalidomide


PubMed Central ID

  • PMC3596960

Scopus Document Identifier

  • 84877620340

Digital Object Identifier (DOI)

  • 10.1182/blood-2012-08-448563

PubMed ID

  • 23299315

Additional Document Info


  • 121


  • 11